Skip to main content
. 2019 Aug 6;2019:3719643. doi: 10.1155/2019/3719643

Figure 1.

Figure 1

GP increases cell viability induced by DEX in C2C12 myotubes. (a) The MTT assay was used to analyze the cytotoxicity of GP (2.5–40 μg/mL) in C2C12 myotubes after treatment for 24 and 48 h. (b) C2C12 myotubes were treated with GP (2.5–40 μg/mL) for 24 h after incubation with DEX for 24 h. The viability of C2C12 myotubes was assessed by the MTT assay. (c) C2C12 myotubes were treated with BSA (2.5–40 μg/mL) for 24 h after incubation with DEX for 24 h. The viability of C2C12 myotubes was assessed by the MTT assay. (d) SDS-PAGE analysis of GP and GP hydrolysate. (e) C2C12 myotubes were treated with GP hydrolysate (2.5–40 μg/mL) for 24 h after incubation with DEX for 24 h. The viability of C2C12 myotubes was assessed by the MTT assay. Data are expressed as the mean ± SD (n = 3); ∗∗p < 0.01 and ∗∗∗p < 0.001 compared to the control group; #p < 0.05 and ###p < 0.001 compared to the DEX group.